GlassScriptPhysician profile
John K Randall
NPI 1326076530
$5,945.30
in general payments reported to CMS, 2019-2025
38 companies · $919 in 2025
The $919 reported for 2025 was more than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $701 · 2020: $665 · 2021: $1,189 · 2022: $869 · 2023: $578 · 2024: $1,024 · 2025: $919.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,400 · Education: $121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,399.52 |
| Education | $121.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,515.78 | 2019-2025 | |
| Abbvie INC. | $1,124.12 | 2019-2025 | |
| Janssen Biotech, INC. | $768.35 | 2019-2024 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $187.57 | 2022-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $180.73 | 2021-2025 | Dupixent, Libtayo |
| Genentech USA, INC. | $117.59 | 2019-2023 | Erivedge |
| Leo Pharma INC. | $115.78 | 2021-2025 | Anzupgo |
| Galderma Laboratories, L.P. | $103.10 | 2024-2025 | Nemluvio |
| Genzyme Corporation | $86.64 | 2020-2021 | |
| Amgen INC. | $85.09 | 2019-2021 | |
| Pfizer INC. | $72.37 | 2019-2022 | |
| Lilly USA, LLC | $66.15 | 2019-2025 | Ebglyss, Taltz |
| Ucb, INC. | $57.65 | 2019-2025 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $57.58 | 2019-2020 | |
| Kerecis Limited | $46.31 | 2023-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $40.99 | 2019-2023 | Ameluz, Xepi, Bf-Rhodoled |
| Smith+Nephew, INC. | $37.18 | 2023-2024 | Collagenase Santyl |
| Celgene Corporation | $33.75 | 2024 | Sotyktu |
| Organon LLC | $30.32 | 2024 | |
| Mayne Pharma Commercial LLC | $28.90 | 2022 | |
| Merck Sharp & Dohme LLC | $26.68 | 2019 | |
| Integra Lifesciences Corporation | $23.66 | 2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Allergan, INC. | $20.64 | 2022 | |
| Verrica Pharmaceuticals INC. | $20.02 | 2024 | Ycanth |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $18.82 | 2022 | |
| Dermavant Sciences, INC. | $17.71 | 2024 | Vtama |
| Convatec INC. | $17.45 | 2024 | |
| Incyte Corporation | $16.90 | 2021 | |
| Vyne Pharmaceuticals INC. | $14.74 | 2021 | |
| Genentech, INC. | $12.73 | 2023 | Erivedge |
8 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Randall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.